Tagraxofusp and Azacitidine With Venetoclax in Newly Diagnosed Secondary AML After Hypomethylating Agents
Tagraxofusp and Azacitidine With Venetoclax in Newly Diagnosed Secondary AML After Hypomethylating Agents
Recruiting · NCT05442216 · Registry updated 2026-07-10Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Tagraxofusp and Azacitidine With Venetoclax in Newly Diagnosed Secondary AML After Hypomethylating Agents | Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, acute myeloid leukemia, hematologic disorder, leukemia, myeloid leukemia, neoplasm | Recruiting | Phase 2 | 2026-07-10 | NCT05442216 |
3 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Joshua Zeidner | 1 |
| Stemline Therapeutics, Inc. | 22 |
| University of North Carolina, Chapel Hill | 249 |
7 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| AdventHealth Orlando | Orlando | United States | 147 |
| Atrium Health Wake Forest Baptist Comprehensive Cancer Center | Winston-Salem | United States | 17 |
| Lifespan Health System Rhode Island Hospital | Providence | United States | 1 |
| Penn Medicine Abramson Cancer Center | Philadelphia | United States | 4 |
| Roswell Park Cancer Institute | Buffalo | United States | 382 |
| University of Miami | Miami | United States | 327 |
| University of North Carolina at Chapel Hill | Chapel Hill | United States | 129 |